Onconetix, Inc. SEC filings ONCO
Onconetix, Inc. has 398 filings in SEC EDGAR's recent list, going back to Jul 15, 2019. Its latest annual report, Form ARS, was filed on Oct 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 6, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Current report | Nov 6, 2026 | — |
| 425 | Form 425 | Oct 27, 2026 | — |
| 425 | Form 425 | Oct 23, 2026 | — |
| 425 | Form 425 | Sep 14, 2026 | — |
| EFFECT | Filing | Sep 3, 2026 | — |
| 425 | Form 425 | Sep 3, 2026 | — |
| 425 | Form 425 | Aug 6, 2026 | — |
| 425 | Form 425 | Jul 7, 2026 | — |
| 425 | Form 425 | Jun 24, 2026 | — |
| EFFECT | Filing | Jun 16, 2026 | — |
| CORRESP | Letter to the SEC | Jun 15, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 12, 2026 | — |
| EFFECT | Filing | May 11, 2026 | — |
| EFFECT | Filing | May 7, 2026 | — |
| CORRESP | Letter to the SEC | May 7, 2026 | — |
| UPLOAD | Letter from the SEC | May 5, 2026 | — |
| 425 | Form 425 | Apr 9, 2026 | — |
| 425 | Form 425 | Apr 2, 2026 | — |
| 425 | Form 425 | Mar 31, 2026 | — |
| 425 | Form 425 | Mar 25, 2026 | — |
| 425 | Current report | Feb 12, 2026 | — |
| EFFECT | Filing | Dec 23, 2025 | — |
| CORRESP | Letter to the SEC | Dec 22, 2025 | — |
| D | Filing | Oct 7, 2025 | — |
| UPLOAD | Letter from the SEC | May 2, 2025 | — |
| PRER14A | Revised preliminary proxy statement | Apr 28, 2025 | — |
| NT 10-K | Notification of late filing | Apr 1, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2025 | — |
| EFFECT | Filing | Dec 12, 2024 | — |
| CORRESP | Letter to the SEC | Dec 11, 2024 | — |
| NT 10-Q | Notification of late filing | Nov 15, 2024 | Sep 30, 2024 |
| EFFECT | Filing | Nov 12, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| CORRESP | Letter to the SEC | Nov 12, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 7, 2024 | — |
| D | Filing | Oct 17, 2024 | — |
| NT 10-Q | Form 10-q extension | Aug 14, 2024 | Jun 30, 2024 |
| PRER14A | Revised preliminary proxy statement | Jul 22, 2024 | — |
| EFFECT | Filing | Jul 1, 2024 | — |
| CORRESP | Letter to the SEC | Jun 28, 2024 | — |
| PRER14A | Revised preliminary proxy statement | Jun 25, 2024 | — |
| CORRESP | Letter to the SEC | Jun 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2024 | — |
| CORRESP | Letter to the SEC | Jun 13, 2024 | — |
| PRER14A | Revised preliminary proxy statement | Jun 5, 2024 | — |
| NT 10-Q | Notification of late filing | May 15, 2024 | Mar 31, 2024 |
| UPLOAD | Letter from the SEC | May 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 26, 2024 | — |
| NT 10-K | Notification of late filing | Apr 1, 2024 | Dec 31, 2023 |
| UPLOAD | Letter from the SEC | Mar 12, 2024 | — |
| NT 10-Q | Notification of late filing | Nov 15, 2023 | Sep 30, 2023 |
| NT 10-Q | Filing | Aug 15, 2023 | Jun 30, 2023 |
| EFFECT | Filing | May 4, 2023 | — |
| EFFECT | Filing | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 14, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 13, 2023 | — |
| EFFECT | Filing | Sep 19, 2022 | — |
| CORRESP | Letter to the SEC | Sep 14, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 7, 2022 | — |
| EFFECT | Filing | May 20, 2022 | — |
| CERT | Filing | Feb 17, 2022 | — |
| 8-A12B | For registration of certain classes | Feb 17, 2022 | — |
| SEC STAFF LETTER | Filing | Feb 16, 2022 | — |
| EFFECT | Filing | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Feb 11, 2022 | — |
| CORRESP | Letter to the SEC | Dec 13, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2021 | — |
| CORRESP | Letter to the SEC | Nov 29, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 18, 2021 | — |
| SEC STAFF LETTER | Filing | Nov 17, 2021 | — |
| CORRESP | Letter to the SEC | Nov 4, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 21, 2021 | — |
| CORRESP | Letter to the SEC | Oct 8, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2021 | — |
| DRS | Filing | Aug 23, 2021 | — |
| D | Filing | Jul 15, 2019 | — |
Showing 82 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ONCO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cincinnati, OH
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782107
- Former names
- Blue Water Biotech, Inc. (until Dec 18, 2023); Blue Water Vaccines Inc. (until Apr 20, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.